Life Time Group Holdings Inc. Common Stock vs Natera Inc. Common Stock — how do they compare? Life Time Group Holdings Inc. Common Stock trades at $40.07 (market cap $8.86B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 6.4× Life Time Group Holdings Inc. Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Life Time Group Holdings Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Life Time Group Holdings Inc. Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| LTH | NTRA | |
|---|---|---|
Market Cap | $8.86B | $57.03B |
Volume | 3,372,885 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $45.73 | $425.64 |
52-Week Low | $24.59 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $12.91B | $56.18B |
Signals from Pluang's Aura AI — not financial advice
Life Time Group Holdings (LTH) trades at $39.66, down 1.76% today, amid bullish technical signals and strong fundamental performance. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.48 exceeding expectations by 28%. Recent expansion news includes new athletic clubs in Florida and Boston, highlighting growth initiatives. Analyst consensus remains strongly bullish with an 86.7% buy rating and $55.17 price target, implying 39% upside.
LTH presents a compelling growth story with expanding facilities and robust profitability margins. Key risks include execution of expansion plans and consumer discretionary spending sensitivity. The valuation at 21.7x P/E appears reasonable given 13% net margins and double-digit ROE. Near-term catalyst is Q3 2026 earnings on October 29, 2026, which could validate the bullish analyst outlook.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Life Time operates fitness and lifestyle centers that offer gyms, classes, sports facilities, and wellness services.
Read more on LTH →Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →